Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 12, 2010, Pages 2658-2665

  Paul, Mical ^a,b   Kariv, Galia ^a,b   Goldberg, Elad ^a,b   Raskin, Maria ^a   Shaked, Hila ^a   Hazzan, Rawi ^a   Samra, Zmira ^a,b   Paghis, Dina ^a,b   Bishara, Jihad ^a,b   Leibovici, Leonard ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Glycopeptides; Hospital acquired infections; Meta analysis; MRSA; Vancomycin

Indexed keywords

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BLOOD CULTURE; CHEMOTHERAPY; CLINICAL EVALUATION; CLINICAL TRIAL; CORTICOSTEROID THERAPY; FOREIGN BODY; GOOD CLINICAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MEDLINE; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; URINARY CATHETER;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; BLOOD; COHORT STUDIES; CROSS INFECTION; CULTURE MEDIA; FEMALE; HUMANS; MALE; MEDICATION ERRORS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

EID: 78149483462     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq373     Document Type: Article

References (45)

1. EARSS 2009. European Antimicrobial Resistance Surveillance System. http://www.rivm.nl/earss/database/ (26 June 2010, date last accessed).
2. Hidron AI, Edwards JR, Patel J et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcareassociated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008; 29: 996-1011.
3. Moore CL, Hingwe A, Donabedian SM et al. Comparative evaluation of epidemiology and outcomes of methicillin-resistant Staphylococcus aureus (MRSA) USA300 infections causing communityand healthcare-associated infections. Int J Antimicrob Agents 2009; 34: 148-55.
4. Shapiro A, Raman S, Johnson M et al. Community-acquired MRSA infections in North Carolina children: prevalence, antibiotic sensitivities, and risk factors. N C Med J 2009; 70: 102-7.
5. Fang CT, Shau WY, Hsueh PR et al. Early empirical glycopeptide therapy for patients with methicillin-resistant Staphylococcus aureus bacteraemia: impact on the outcome. J Antimicrob Chemother 2006; 57: 511-9.
6. Gomez J, Garcia-Vazquez E, Banos R et al. Predictors of mortality in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: the role of empiric antibiotic therapy. Eur J Clin Microbiol Infect Dis 2007; 26: 239-45.
7. Kim SH, Park WB, Lee KD et al. Outcome of inappropriate initial antimicrobial treatment in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2004; 54: 489-97.
8. Marchaim D, Kaye KS, Fowler VG et al. Case-control study to identify factors associated with mortality among patients with methicillinresistant Staphylococcus aureus bacteraemia. Clin Microbiol Infect 2010; 16: 747-52.
9. Rodriguez-Bano J, Millan AB, Dominguez MA et al. Impact of inappropriate empirical therapy for sepsis due to health care-associated methicillin-resistant Staphylococcus aureus. J Infect 2009; 58: 131-7.
10. Roghmann MC. Predicting methicillin resistance and the effect of inadequate empiric therapy on survival in patients with Staphylococcus aureus bacteremia. Arch Intern Med 2000; 160: 1001-4.
11. Schramm GE, Johnson JA, Doherty JA et al. Methicillin-resistant Staphylococcus aureus sterile-site infection: the importance of appropriate initial antimicrobial treatment. Crit Care Med 2006; 34: 2069-74.
12. Leibovici L, Paul M. Comment on Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006; 58: 220.
13. Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 1995; 44: 1-13.
14. Gould FK, Brindle R, Chadwick PR et al. Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. J Antimicrob Chemother 2009; 63: 849-61.
15. Leibovici L, Samra Z, Konigsberger H et al. Long-term survival following bacteremia or fungemia. JAMA 1995; 274: 807-12.
16. Ottenbacher KJ, Ottenbacher HR, Tooth L et al. A review of two journals found that articles using multivariable logistic regression frequently did not report commonly recommended assumptions. J Clin Epidemiol 2004; 57: 1147-52.
17. Conterno LO, Wey SB, Castelo A. Risk factors for mortality in Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 1998; 19:32-7.
18. Gomez J, Garcia-Vazquez E, Banos R et al. [Methicillin susceptible Staphylococcus aureus bacteremia: epidemiology and prognostic factors. A prospective study 2000-2003]. Rev Clin Esp 2007; 207: 57-63.
19. Kaech C, Elzi L, Sendi P et al. Course and outcome of Staphylococcus aureus bacteraemia: a retrospective analysis of 308 episodes in a Swiss tertiary-care centre. Clin Microbiol Infect 2006; 12: 345-52.
20. Khatib R, Saeed S, Sharma M et al. Impact of initial antibiotic choice and delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2006; 25: 181-5.
21. Kim SH, Park WB, Lee CS et al. Outcome of inappropriate empirical antibiotic therapy in patients with Staphylococcus aureus bacteraemia: analytical strategy using propensity scores. Clin Microbiol Infect 2006; 12: 13-21.
22. Lesens O, Brannigan E, Bergin C et al. Impact of the use of aminoglycosides in combination antibiotic therapy on septic shock and mortality due to Staphylococcus aureus bacteremia. Eur J Intern Med 2006; 17: 276-80.
23. Lin MY, Weinstein RA, Hota B. Delay of active antimicrobial therapy and mortality among patients with bacteremia: impact of severe neutropenia. Antimicrob Agents Chemother 2008; 52: 3188-94.
24. Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis 2005; 52: 113-22.
25. Marra AR, Edmond MB, Forbes BA et al. Time to blood culture positivity as a predictor of clinical outcome of Staphylococcus aureus bloodstream infection. J Clin Microbiol 2006; 44: 1342-6.
26. Naber CK, Baddour LM, Giamarellos-Bourboulis EJ et al. Clinical consensus conference: survey on Gram-positive bloodstream infections with a focus on Staphylococcus aureus. Clin Infect Dis 2009; 48 Suppl 4: S260-70.
27. Soriano A, Marco F, Martinez JA et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46: 193-200.
28. Soriano A, Martinez JA, Mensa J et al. Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. Clin Infect Dis 2000; 30: 368-73.
29. Ammerlaan H, Seifert H, Harbarth S et al. Adequacy of antimicrobial treatment and outcome of Staphylococcus aureus bacteremia in 9 Western European countries. Clin Infect Dis 2009; 49: 997-1005.
30. Schweizer ML, Furuno JP, Harris AD et al. Empiric antibiotic therapy for Staphylococcus aureus bacteremia may not reduce in-hospital mortality: a retrospective cohort study. PLoS ONE 2010; 5: e11432.
31. Goldberg E, Paul M, Talker O et al. Co-trimoxazole versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteraemia: a retrospective cohort study. J Antimicrob Chemother 2010; 65: 1779-83.
32. Haque NZ, Cahuayme Zuniga L, Peyrani P et al. Relationship of vancomycin MIC to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated and healthcare-associated pneumonia. Chest 2010; doi:10.1378/chest.09-2453.
33. Sakoulas G, Moise-Broder PA, Schentag J et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42: 2398-402.
34. Lin SH, Liao WH, Lai CC et al. Risk factors for mortality in patients with persistent methicillin-resistant Staphylococcus aureus bacteraemia in a tertiary care hospital in Taiwan. J Antimicrob Chemother 2010; 65: 1792-8.
35. Wang JL, Wang JT, Sheng WH et al. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC=2mg/L, by the broth microdilution method. BMC Infect Dis 2010; 10: 159.
36. Takesue Y, Nakajima K, Takahashi Y et al. Clinical characteristics of vancomycin minimum inhibitory concentration of 2 mg/ml methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia. J Infect Chemother 2010; doi:10.1007/s10156-010-0086-0.
37. Yoon YK, Kim JY, Park DW et al. Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin. J Antimicrob Chemother 2010; 65: 1015-8.
38. Jung YJ, Koh Y, Hong SB et al. Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia. Crit Care Med 2010; 38: 175-80.
39. Chang FY, Peacock JE Jr, Musher DM et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003; 82: 333-9.
40. Kim SH, Kim KH, Kim HB et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2008; 52: 192-7.
41. Lodise TP Jr, McKinnon PS, Levine DP et al. Impact of empiricaltherapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51: 3731-3.
42. Siegman-Igra Y, Reich P, Orni-Wasserlauf R et al. The role of vancomycin in the persistence or recurrence of Staphylococcus aureus bacteraemia. Scand J Infect Dis 2005; 37: 572-8.
43. Stryjewski ME, Szczech LA, Benjamin DK Jr et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysisdependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 2007; 44: 190-6.
44. Paul M, Andreassen S, Tacconelli E et al. Improving empirical antibiotic treatment using TREAT, a computerized decision support system: cluster randomized trial. J Antimicrob Chemother 2006; 58: 1238-45.
45. Paul M, Nielsen AD, Goldberg E et al. Prediction of specific pathogens in patients with sepsis: evaluation of TREAT, a computerized decision support system. J Antimicrob Chemother 2007; 59: 1204-7.